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Abstract
Background: Antibiotic resistance is an urgent global problem, but reversibility is poorly understood. We examined
the development and decay of bacterial resistance in community patients after antibiotic use.
Methods: This was a systematic review and meta-analysis. PubMed, EMBASE and CENTRAL (from inception to May
2017) were searched, with forward and backward citation searches of the identified studies. We contacted authors
whose data were unclear, and of abstract-only reports, for further information. We considered controlled or times-
series studies of patients in the community who were given antibiotics and where the subsequent prevalence of
resistant bacteria was measured. Two authors extracted risk of bias and data. The meta-analysis used a fixed-effects
model.
Results: Of 24,492 articles screened, five controlled and 20 time-series studies (total 16,353 children and 1461 adults)
were eligible.
Resistance in Streptococcus pneumoniae initially increased fourfold after penicillin-class antibiotic exposure [odds ratio
(OR) 4.2, 95% confidence interval (CI) 3.5–5.4], but this fell after 1 month (OR 1.7, 95% CI 1.3–2.1). After cephalosporin-
class antibiotics, resistance increased (OR 2.2, 95%CI 1.7-2.9); and fell to (OR 1.6, 95% CI 1.2-2.3) at 1 month. After
macrolide-class antibiotics, resistance increased (OR 3.8, 95% CI 1.9–7.6) and persisted for 1 month (OR 5.2, 95%
CI 2.6–10.3) and 3 months (OR 8.1, 95% CI 4.6–14.2, from controlled studies and OR 2.3, 95% CI 0.6–9.4, from time-series
studies).
Resistance in Haemophilus influenzae after penicillins was not significantly increased (OR 1.3, 95% CI 0.9–1.9) initially but
was at 1 month (OR 3.4, 95% CI 1.5–7.6), falling after 3 months (OR 1.0, 95% CI 0.5–2.2). Data were sparse for
cephalosporins and macrolides.
Resistance in Enterobacter increased post-exposure (OR 3.2, 95% CI 0.9–10.8, from controlled studies and OR 7.1,
95% CI 4.2–12, from time-series studies], but was lower after 1 month (OR 1.8, 95% CI 0.9–3.6).
Conclusions: Resistance generally increased soon after antibiotic use. For some antibiotic classes and bacteria, it
partially diminished after 1 and 3 months, but longer-term data are lacking and urgently needed.
Trial registration: PROSPERO CRD42015025499.
* Correspondence: cdelmar@bond.edu.au
Centre for Research in Evidence-Based Practice (CREBP), Faculty of Health
Sciences and Medicine, Bond University, Gold Coast, QLD 4229, Australia
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Background
The discovery of penicillin in the mid-20th century her-
alded the antibiotic era [1, 2] and contributed significantly
to a decrease in the rates of morbidity and mortality that
had been caused by previously life-threatening infections
[3, 4]. However, antibiotic resistance emerged shortly
afterwards [5]. This drove the discovery of new antibiotics
[4]. However, the development of new antibiotics is no
longer keeping up with resistance [6] and we now face the
threat of a post-antibiotic era [7–9].
Antibiotic resistance is generated by its use [7]. One
area of interest is the high use of antibiotics in primary
care, particularly for the treatment of acute respiratory
infections, for which there is very little or no benefit
[10–14]. Yet many clinicians in primary care persist, be-
lieving that resistance is not their problem [15–17].
Systematic reviews suggest that prescribing antibiotics
in primary care initially increases the prevalence of resist-
ant bacteria in patients—more so in countries with higher
prescribing rates [18]—but that they became less detect-
able in the microbiome after 12 months [19]. The return
of the microbiome to antibiotic susceptibility is critical in
encouraging a reduction of antibiotic use, which is being
actively pursued in the primary-care community inter-
nationally to minimise antibiotic resistance. What remains
unknown is the time this takes, and how it varies by anti-
biotic class and bacterium.
This information is important for informing public health
messages, antibiotic resistance campaigns and clinician
training. This systematic review aimed to identify and syn-
thesise prospective studies that have examined the occur-
rence of bacterial resistance in community-based patients
who were exposed to antibiotics, and to explore whether
resistance decay varies by antibiotic class and bacterium.
Methods
We initially planned simply to update a previous systematic
review that had addressed resistance decay [19]. However,
we were unable to replicate the search (since there were
discrepancies in the numbers of studies found and differ-
ences in the eligible and included studies identified) and
also realised that the time points were poorly discriminated,
especially those from retrospective studies. The design of
retrospective studies means that: (1) they can report only
the time interval between antibiotic exposure and the isola-
tion of resistant isolates at the end of the study, with no
data in between; (2) details of the exposure antibiotic, such
as type and dose, are often unknown and (3) there is often
a selection bias towards patients with treatment failure. Ac-
cordingly, we undertook this review de novo.
This research was reported in line with the Preferred
Reporting Items for Systematic Reviews and Meta Ana-
lyses (PRISMA) [20].
Eligible study designs
Eligible studies compared antibiotic-exposed participants
to controls (including randomised controlled trials or
RCTs), or involved prospective repeat measure cohorts
that reported the prevalence of resistant bacteria among
patients, isolates or specimens (percentage of resistant iso-
lates from each swab) over time. Retrospective studies
were also identified as part of the same search process but
will be reported separately. Case reports were ineligible.
Eligible participants
We included studies of patients (or isolates from them), of
any sex or age, symptomatic or asymptomatic, who were
treated in the community or had community-acquired infec-
tions. Studies that included patients with hospital-associated
infections, device-related infections and persistent infections
were ineligible (Table 2 in the Appendix).
Eligible types of antibiotic exposure
We included any study in which participants in the
index group were exposed to a short antibiotic course
(≤2 weeks), of any antibiotic class.
Eligible comparison
Groups of participants who either did not use antibiotics
(controls) or used them at different times were eligible
as comparators.
Outcomes
The primary outcome was the isolation of resistant
bacteria at a pre-specified time point. Studies that did
not report the duration between the last known anti-
biotic exposure and isolation of resistant bacteria, or
did not report the before and after prevalences of re-
sistant and susceptible isolates in studies comparing
two antibiotic exposures, were excluded.
Search and information sources
We searched PubMed, EMBASE and the Cochrane
Central Register of Controlled Trials (CENTRAL)
from inception until the first week of May 2017,
using medical subject headings (MeSH) and keywords:
‘Drug Resistance’ AND ‘Anti-Bacterial Agents‘ AND
‘Primary Health Care‘ AND ‘Patients‘ with a detailed
search strategy (Table 3 in the Appendix). Forward
and backward citation searches identified additional
relevant studies. We contacted authors whose data
were unclear, and of abstract-only reports, for further
information.
Study selection
Two researchers (MB and JR) independently screened
the titles and abstracts of search results using End-
note (version X8) and the Rayyan website for
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systematic reviews [21], and then the full texts of
remaining studies for inclusion. A third reviewer
(CDM or TH) resolved any disagreements.
Data extraction
Two researchers (MB and AS) used a pre-specified and
pre-piloted form to independently extract data on: study
design, study duration, symptomatic or asymptomatic
patients, age, recruitment location, total number of re-
ported patients and isolates, methods of sampling, and
collection of antibiotic exposure data and analysis. Dis-
agreements were resolved by consensus or third author
(CDM or TH).
Assessment of risk of bias
Two researchers (MB and AS) independently
evaluated the risk of bias, using the Cochrane Risk
of Bias tool [22] for RCTs, or, for other study de-
signs, items adapted from the Risk of Bias in
Non-randomised Studies, Interventions (ROBINS-I)
tool [23] (Box 1).
Fig. 1 Study flow chart
Box 1 Items adopted from the ROBINS-I tool for the
cohort studies in this review
• Bias due to confounding:
- Confounding factors were adjusted in the analysis (low risk)
- Confounding factors were measured and showed balance
(low risk)
- Randomised comparison (low risk)
• Bias due to missing data (follow-up data):
- Bias that arises when a later follow-up is missing for individuals
initially included (low risk <20%)
• Bias in measurement of outcomes (who measured resistance):
- Independent lab (low risk)
- Independent technician (low risk)
- Study researchers (high risk)
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Data analysis
We derived the odds of identifying resistance at different
time points.
Some studies limited the denominator to partici-
pants carrying bacteria and others to total partici-
pants (those carrying bacteria or not). We included
only data from participants carrying bacteria, which
enabled comparisons, as we are interested in the
burden of resistance on the community. We ex-
tracted incident cohort counts, where reported. If
they were not, we manually calculated them from
odds ratios (ORs). When resistance data were re-
ported for more than one antibiotic, we analysed
only resistance to the same antibiotic to which par-
ticipants were exposed (to avoid duplication), and
co-resistance data were extracted and reported in
separate tables. Some studies reported resistance as
‘intermediate’ and ‘high’: we collapsed these into
‘resistant’.
We use the term ‘prospective repeated measures
cohort studies’ to describe those that were rando-
mised trials by design but in which the data were
extracted from each arm of the trial separately with-
out the benefit of randomisation. These were ana-
lysed with the cohort studies. The main study
designs are detailed in Table 1.
Resistance prevalence data can be compared at
different time points in two ways, according to
study design: a separate control group (methodo-
logically more robust) or studies reporting before
and after antibiotic exposure. We meta-analysed the
two methods separately, but present them
adjacently.
To facilitate comparisons, we collapsed the re-
ported time periods after antibiotic exposure to
pre-specified ranges: pre-exposure and from end of
treatment (i.e. time 0): 0 to ≤1 week, >1 week to
≤1 month and >1 to ≤3 months. When the same
study reported multiple resistance data that fell in
the same pre-specified ranges, we chose the latest
time point provided.
We undertook the meta-analysis using RevMan
Version 5.3 [24], pooling Peto ORs from the end of
treatment with a fixed-effects model to correct bet-
ter for zero cell counts [22]. We assessed statistical
heterogeneity among studies with a χ2 test (using
P ≤ 0.05 for significant heterogeneity) and I2. Sub-
group analyses were pre-specified by the time since
last antibiotic exposure. We were not able to test
for statistical differences between different times
using either a statistical test for trend or a χ2 test
for heterogeneity of the different time subgroups, as
some studies provided data for different time points,
but not all.
Protocol and registration
The review protocol was registered on the PROSPERO
database (CRD42015025499) at http://www.crd.york.a-
c.uk/PROSPERO/display_record.php?ID=CRD42015025
499. Ethics approval was not required. A modification
of the protocol was to clarify that studies that had re-
ported resistant bacteria at the isolate level were also
eligible.
Results
Study selection
Our search found 24,117 citations, supplemented by
5878 citations identified from forward and backward
searches of references cited in included studies,
which, after removing duplicates, left 24,492. Screen-
ing by title and abstract excluded 23,934, leaving
558 for which the full text was screened. After ex-
cluding 379 (Table 4 in the Appendix gives detailed
reasons for exclusion), 179 eligible articles remained,
of which 25 studies (in 26 articles) assessed the iso-
lation of resistant bacteria prospectively. These were
included in this review (Fig. 1).
Study characteristics
Of the included studies, five were RCTs [25–29]
and 20 were prospective cohort studies [30–50]. We
report the study design here in relation to the out-
come of resistance, although some studies were
RCTs for the outcome of efficacy. Table 1 shows
study characteristics. All but three [26, 29, 39] were
conducted in one of the Organisation for Economic
Co-operation and Development countries:
 16 investigated children (total of 16,353) [26,
29–34, 36–41, 44, 45, 48–50] and 8 studied
adults (total of 1461) [25, 27, 28, 35, 42, 43, 46,
47
]
 14 investigated symptomatic patients (12 with
respiratory infections [28, 30–34, 36–38, 48–50],
1 with a urinary infection [42] and 1 with acute
febrile illness [47])
 6 involved asymptomatic participants [25, 27, 29,
35, 43, 46]
 5 studies included both symptomatic and
asymptomatic participants [26, 39, 41, 44, 45]
Twelve studies compared antibiotic exposure against a
control or placebo [25–31, 39, 41, 43, 45, 47] and 13
were antibiotic comparison studies [32–38, 42, 44, 46,
48–50]. Antibiotics from the following classes were stud-
ied: penicillins (14) [28, 30–38, 41, 48–50], macrolides
(12) [25–27, 29, 37, 39, 41, 44, 46, 49, 50], cephalosporin
(8) [31–33, 36–38, 49, 50], sulphonamides and
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trimethoprim (2) [42, 45], quinolones (1) [46], lincomycin
(1) [43] and ketolides (1) [35]. One study included any
antibiotic [47].
Risk of bias in studies and heterogeneity assessment
The risk of bias was assessed based on the study
design for the outcome of resistance, not the ori-
ginal study design for the outcome of efficacy. The
overall risk of bias was low, although bias due to
selective reporting was uncertain for most RCTs be-
cause resistance was often not nominated as an out-
come and there was an unclear risk of bias for the
outcome measurement in the cohort studies (Fig. 2).
We were not able to test for publication bias for
the examined outcomes because of the very low
number of studies in each funnel plot (Fig. 8 in the
Appendix). There was considerable variation in the
heterogeneity between studies, particularly for the
cohort studies (Figs. 3, 4 and 5).
Resistance in respiratory tract bacteria
Bacteria were isolated from the respiratory tract in 19
studies and from the conjunctiva in one study.
Streptococcus pneumoniae and penicillin exposure
Penicillin-resistant Streptococcus pneumoniae were
studied in only one controlled study (with 35 partic-
ipants). Before exposure to penicillin, resistance was
not significantly different between the group of pa-
tients subsequently exposed and those not exposed
[OR 2.8, 95% confidence interval (CI) 0.5–15.3].
After exposure, the OR of resistance in those ex-
posed was 9.4 (95% CI 0.6–149.3). After 3 months,
there was no longer a significant difference in resist-
ance (OR 0.4, CI 0.02–9.8; Fig. 3).
There were more data from prospective repeated
measures cohort studies that compared resistance
rates before antibiotic exposure (baseline data) and
after penicillin exposure after 1 week (0 to 7 days; 6
studies, 1060 participants and 8 antibiotic exposure
groups) and after 1 month (>1 week to ≤1 month; 4
studies, 772 participants and 5 antibiotic exposure
groups). After 1 week, resistance had increased sig-
nificantly (OR 4.2, 95% CI 3.3–5.4). Thereafter, re-
sistance had reduced after 1 month (OR 1.7, 95% CI
1.3–2.1; Fig. 3).
One RCT [28] investigated reported resistance in iso-
lates (rather than individuals) after exposure to
Fig. 2 a. Risk of bias graph: review authors’ judgments about each risk of bias item presented as percentages across all included studies. b. Risk
of bias summary: review authors’ judgements about each risk of bias item for each included study. RCT randomised controlled trial
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amoxicillin and its data are analysed separately. It found
that the changes in resistance following amoxicillin ex-
posure were short-lived, returning to normal by 1 month
after the end of treatment (Fig. 3).
S. pneumoniae and cephalosporin exposure
There were no RCTs. Four cohort studies (519 partici-
pants and 8 different antibiotic exposure groups) re-
ported that resistance had increased at 1 week after
exposure (OR 2.2, 95% CI 1.7–2.9), persisting after 1
month (OR 1.6, 95% CI 1.2–2.3; Fig. 3).
S. pneumoniae and macrolide exposure
There were three controlled studies. After a month,
one small study reported the OR of resistance was
6.3 (95% CI 0.4–103.2). In three studies (437 partici-
pants), it remained high (OR 8.1, 95% CI 4.6–14.2) at
3 months. An RCT [27] of isolates found that a single
course of macrolide-class antibiotics caused increased
resistance in the first week immediately after macro-
lide use, and resistance remained significantly higher
than the placebo group for more than 3 months (data
not shown).
Three cohort studies (101 participants and 3 differ-
ent antibiotics) reported increased resistance at 1 week
(OR 3.8, 95% CI 1.9–7.6). Three studies (147 partici-
pants and 3 different antibiotics) found that after 1
month, resistance was increased (OR 5.2, 95% CI 2.6–
10.3). There were 3-month data from only one study
(OR 2.3, 95% CI 0.6–9.4; Fig. 3).
Haemophilus influenzae and penicillin exposure
Two RCTs (117 participants) found comparable resist-
ance between groups before exposure to penicillin
(OR 0.8, 95% CI 0.4–1.7). One week after exposure,
resistance had increased non-significantly in one RCT
(with only 4 participants; OR 7.4, 95% CI 0.2–374).
Increased resistance persisted for 1 month in another
RCT (102 participants; OR 3.4, 95% CI 1.5–7.6). At 3
months, in this study, resistance had returned to nor-
mal (OR 1.0, 95% CI 0.5–2.2).
In four cohort studies (356 participants and 5 different
antibiotic exposure groups), resistance was not increased
Fig. 3 Pooled odds ratios for resistance in respiratory tract bacteria (Streptococcus pneumoniae) and antibiotic exposure by class. Studies grouped
by time from the end of antibiotic exposure. CI confidence interval, df degrees of freedom, RCT randomised controlled trial
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at 1 week (OR 1.3, 95% CI 0.9–1.9). In two of the four
cohort studies (183 participants and 3 different anti-
biotic exposure groups), it remained not increased at
1 month (OR 1.3, 95% CI 0.7–2.2; Fig. 4).
H. influenzae and cephalosporin exposure
There were no RCTs. Three cohort studies (229 partici-
pants and 3 different antibiotic exposure groups) found
resistance had not increased at 1 week (OR 1.2, 95% CI
0.7–1.9) or at 1 month (255 participants; OR 1.3, 95% CI
0.9–2; Fig. 4).
H. influenzae and macrolide exposure
One RCT (175 participants) reported data at two time
points. Before exposure, resistance was not signifi-
cantly different between groups (0.6, 95% CI 0.3–1.3)
and directly after macrolide exposure, resistance had
increased in the exposed group (OR 2.5, 95% CI 0.8–
8.2). One cohort study also reported two time points.
Resistance had increased after exposure at 1 month
(OR 2.0, 95% CI 0.3–12.9) and it had decreased by 3
months (OR 0.5, 95% CI 0.1–3.1; Fig. 4).
Resistance in other respiratory bacteria
The heterogeneity in five studies of resistance to non--
groupable streptococci, Moraxella catarrhalis, Staphylo-
coccus aureus, beta-lactamase producers and
Streptococcus mitis, exposed to different antibiotic
classes (penicillins, cephalosporins, macrolides, ketolides
and quinolones), precluded meta-analysis. However,
Fig. 6 in the Appendix shows a forest plot for the
studies.
Resistance in Gram-negative gastrointestinal tract
bacteria to several antibiotics
Trimethoprim and β-lactams exposure: In one RCT
(with 64 participants), before antibiotic exposure, the
OR of isolating resistance was not significantly different
at 0.8 (95% CI 0.3–2.3). Two controlled studies (with
179 participants) compared antibiotic exposure against a
group with no exposure. It found that 1 week after anti-
biotic exposure, the OR of isolating resistant
Gram-negative bacteria was 3.2 (95% CI 0.9–10.8;
Fig. 5).
Trimethoprim and trimethoprim-sulfamethoxazole
exposure: From two cohort studies (129 participants and
3 different antibiotic exposure groups) the OR of isolat-
ing antibiotic-resistant Enterobacteria was 7.1 (95% CI
4.2–12) at 1 week. In one study (with 93 participants
and 2 different antibiotic exposures), the OR was 1.8
(95% CI 0.9–3.6) at 1 month (Fig. 5).
One RCT [43] investigated the consequences of a
1-week course of clindamycin on Bacteroides species
using isolates rather than participants as the unit of
analysis. It reported that the numbers of isolates
Fig. 4 Pooled odds ratios for resistance in respiratory tract bacteria (Haemophilus influenzae) and antibiotic exposure by class. Studies grouped by
time from the end of antibiotic exposure. CI confidence interval, df degrees of freedom
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returned to pre-treatment levels after 3 weeks in the
exposed group. However, the isolates demonstrated
qualitative changes to their diversity, and resistance
genes remained 2 years later (data not shown).
Co-resistance in participants in included studies
Nine of the included studies reported selection for
resistance to a different antibiotic than the exposure
antibiotic (co-resistance). In respiratory isolates, 3
months after azithromycin exposure, the OR of
isolating clindamycin-resistant S. pneumoniae (OR 4,
95% CI 1.6–10.1) and erythromycin-resistant S.
pneumoniae (OR 2.1, 95% CI 1.1–3.9) was
significantly higher between exposed and unexposed
groups. In gastrointestinal tract Enterobacteria,
there was a significant increase in the odds of iso-
lating trimethoprim-resistant bacteria immediately
after exposure to trimethoprim/sulfamethoxazole
(OR 4.5, 95% CI 1.8–11.7; Fig. 7 in the Appendix).
Discussion
Our systematic review found that antibiotic resist-
ance in either the respiratory or gastrointestinal
tracts of people in the community increased imme-
diately after treatment with any of the antibiotics
studied. This generally decayed over the next
month, particularly in S. pneumoniae isolates treated
Fig. 5 Pooled odds ratios for resistance in gastrointestinal tract bacteria and any antibiotic exposure. Studies grouped by time from the end of
antibiotic exposure. -ve, negative, CI confidence interval, df degrees of freedom, SMX sulfamethoxazole, TMP trimethoprim
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with penicillins. The effect of cephalosporins on re-
sistance was less pronounced at 1 week but per-
sisted for at least for a month. After macrolide
exposure, resistance persisted for at least 3 months.
The paucity of controlled studies means there is
some uncertainty around the estimates of the rate
of decay of resistance in the macrolides.
There was no significant difference in isolation of
resistant H. influenzae following penicillin or
cephalosporin exposure. For macrolides, there were
not enough data to examine this. For Gram-negative
bacteria in the gastrointestinal tract, resistant bac-
teria were detectible 1 month after antibiotic expos-
ure, decaying from immediately after exposure.
Antibiotic resistance may well predate the human
exploitation of antibiotics [51]. Our data show that
baseline antibiotic resistance increases after anti-
biotic use. The mechanism by which this happens
includes selection of bacteria with the pre-existing
gene and the acquisition of the resistance gene from
other organisms in the microbiome. Similar
mechanisms may be operating in the reversal of re-
sistance when antibiotics disappear from the host
environment.
This review, with its more up-to-date collection of
studies, more rigorously collected data (from only
prospective studies) and more precise time frames
(which avoid the uncertainty implicit in time-until
periods dictated by retrospective designs), confirms the
broad finding of previous systematic reviews that anti-
biotic exposure results in resistance [18, 19].
It has been reported previously that isolation of
resistant isolates was strongest in the month directly
after exposure and remained detectable for up to
12 months [19]. However, our review provides bet-
ter and more nuanced estimates of the time to
decay of antibiotic resistance after exposure, with
faster decays than previously reported. In addition,
we show that the time frame may vary according to
antibiotic class and bacteria, notwithstanding the
limitations of the primary evidence.
Our search strategy was systematic and transpar-
ent, and found studies that had not been found in
the earlier review of resistance decay [19]. Our
review also provides a higher level of rigour by
excluding studies at high risk of bias due to
confounding variables (such as hospitalisation,
device-associated infections and persistent infec-
tions) and by being careful to align the time periods
after antibiotic exposure (as subgroup analyses)
among the included studies to enable better
comparisons.
There are several limitations of this review. First,
the unadjusted status of the ORs we extracted,
rather than simply importing study authors’ adjust-
ments of some confounders, threatens to introduce
bias from those confounders. There are potentially
many other confounders. For example, resistance
can be acquired through contact with other individ-
uals rather than direct antibiotic exposure, groups
within the included studies may have different base-
line risks for resistance, resistance sampling was not
standardised and indications for antibiotic exposure
and bacterial load (likely to differ between symp-
tomatic and asymptomatic participants, who might
be the only carriers of resistance in their micro-
biome, or between children and adults) might affect
the development of resistance. However, the crude
ORs reported differ little from the adjusted values.
We were not able to investigate any effect of dose
or duration of the antibiotic exposure on resistance.
The quality of how resistance data were analysed
and reported was poor in some studies, and some
authors did not respond to our requests to clarify
aspects of their methods and data, which contributes
to the uncertainty of the review’s estimates. This
could be because reporting of resistance was not the
primary objective in most of the included studies. Fi-
nally, resistance was reported in most studies as the
proportion of resistant isolates, which does not take
account of the changes in overall bacterial popula-
tion, which is likely to decrease from the antibiotic
effect. Consequently, a rise in the resistance propor-
tion might disguise a decrease in the absolute num-
bers of resistant bacteria.
Urgently needed is further research with high-quality
placebo-controlled trials that measure the numbers of
resistant and susceptible isolates and enable compari-
sons of antibiotic dose, duration and class against differ-
ent bacteria.
Conclusions
Antibiotic use increases the consequent isolation of
bacterial resistance in individuals. The odds of resist-
ance developing and the time of return to bacterial
susceptibility may vary by antibiotic class. It appears
that decay after exposure to antibiotics may be faster
than previously reported [19] for penicillins against
respiratory S. pneumoniae, and perhaps H. influen-
zae, although this may not be true for other antibi-
otics such as macrolides, where resistance might
persist longer. This may be another factor for clini-
cians to consider when choosing an antibiotic, espe-
cially for minor infections. More primary research
focussing on resistance development and decay is
needed to further inform clinical decisions and pub-
lic health policies.
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Table 2 Elaboration on the inclusion and exclusion criteria
Inclusion criteria Exclusion criteria Rationale for exclusion criteria
Population Symptomatic and
asymptomatic patients
(healthy people)
Hospitalised patients with infections
>48 h after admission
Increased risk of colonisation with drug-resistant
bacteria from the hospital environment
Hospitalised patients with a
community infection
(<48 h from admission)
Patients with post-surgery infections
Burn-associated infections
Sample of health-care workers, medical or
nursing students with medical rotations
ICU patients referred from hospital wards or
patients with central-line-associated blood
stream infections
High probability that these patients are infected
with resistant bacteria
Patients with device-related infections
(catheter, implants, dialysis-associated
infections or ventilation-associated infections)
Devices are more prone to infection with resistant
bacteria
Patients with persistent diseases (tuberculosis,
H. pylori, syphilis, Pseudomonas aeruginosa,
Mycobacterium leprae or Salmonella typhi)
Asymptomatic infections that remains undetected
for a long duration; these require prolonged
antibiotic treatments and it is considered treatment
failure if the bacterium is isolated after treatment
>50% of the sample are
immunocompromised patients
Infections due to opportunistic bacteria that
normally do not cause infections
Patients with cystic fibrosis or bronchiectasis
and cancer patients
Comorbidities that increase the risk of infection
Intervention Any antibiotic exposure for any
infection <14 days
(prospective or retrospective)
Long-term antibiotic treatment
>2 continuous weeks
Higher probability of killing susceptible organisms
and increased risk of carriage of resistant isolates
Control/
comparator
Patients without antibiotic
exposure
Patients with a different antibiotic
exposure, dose, frequency or
route of administration
If there are no before and after
measurements of resistance
Outcome Prevalence of resistance in
exposed and unexposed patients
If there are no before and after
measurements of resistance
Duplicate isolate reporting
Time Time between antibiotic
exposure and isolation of
resistant organisms
Studies were excluded if there were no data
available on the last known antibiotic
exposure
Setting Primary care
General practices
Outpatient clinics
Paediatric clinics
Emergency department
ICU intensive care unit
Appendix
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Table 3 Search strategy
PubMed
(‘Drug Resistance‘[Mesh] OR Resistance[tiab] OR Resistant[tiab]
OR Multiresistant[tiab])
AND
(‘Anti-Bacterial Agents‘[Mesh] OR ‘Macrolides‘[Mesh] OR ‘beta-
Lactams‘[Mesh] OR Antibacterial[tiab] OR Antibacterials[tiab] OR
Antibiotics[tiab] OR Antibiotic[tiab] OR Macrolides[tiab] OR
Macrolide[tiab] OR beta-Lactams[tiab] OR Antimicrobial[tiab] OR Antimi
crobials[tiab] OR Penicillin[tiab] OR Methicillin[tiab] OR ampicillin[tiab]
OR azithromycin[tiab] OR Cephalexin[tiab])
AND
(‘Population Surveillance‘[Mesh] OR ‘Primary Health Care‘[Mesh] OR
‘Ambulatory Care‘[Mesh] OR ‘Outpatients‘[Mesh] OR ‘Community-
Acquired Infections‘[Mesh] OR ‘Demography‘[Mesh] OR ‘Carrier
State‘[Mesh] OR ‘Endemic Diseases‘[Mesh] OR ‘Primary care’[tiab] OR
‘Primary healthcare’[tiab] OR ‘Family practice’[tiab] OR ‘General
practice’[tiab] OR Ambulatory[tiab] OR Outpatients[tiab] OR
Outpatient[tiab] OR Community[tiab] OR Communities[tiab] OR
Surveillance[tiab] OR Carrier[tiab] OR Carriage[tiab] OR Area[tiab] OR
Areas[tiab] OR Region[tiab] OR Regions[tiab] OR Demographic[tiab])
AND
(‘Drug Prescriptions‘[Mesh] OR ‘Prescriptions‘[Mesh] OR ‘therapeutic
use’[sh] OR Prescriptions[tiab] OR Prescription[tiab] OR Prescribing[tiab]
OR Prescribe[tiab] OR Prescribed[tiab] OR Consumption[tiab] OR
Courses[tiab] OR Course[tiab] OR Programme[tiab] OR Programmes[tiab]
OR Dose[tiab] OR Doses[tiab] OR Exposure[tiab] OR Isolates[tiab] OR
Isolated[tiab] OR Risk[ti])
AND
(‘Patients‘[Mesh] OR ‘Drug therapy’[sh] OR ‘Drug effects’[sh] OR
Microbiology[sh] OR Treatment[tiab] OR Patient[tiab] OR Patients[tiab]
OR Patient’s[tiab])
AND
(‘Randomised Controlled Trial’[pt] OR ‘Controlled Clinical Trial’[pt] OR
‘Epidemiologic Studies‘[Mesh] OR Randomly[tiab] OR Randomised[tiab]
OR Randomised[tiab] OR Group[tiab] OR Groups[tiab] OR Control[tiab]
OR Controlled[tiab] OR Case[tiab] OR Cases[tiab] OR Multicenter OR
Center[tiab] OR Centre[tiab] OR Trial[tiab] OR Trials[tiab] OR
Compare[tiab] OR Compared[tiab] OR Comparison[tiab] OR Cohort[tiab]
OR Observed[tiab] OR Observational[tiab] OR Questionnaires[tiab] OR
Questionnaires[tiab] OR Frequency[tiab] OR Frequencies[tiab] OR
Baseline[tiab] OR Modelling[tiab])
NOT
(‘Hospitals‘[Mesh] OR ‘Inpatients’[Mesh] OR ‘Cross Infection‘[Mesh] OR
Hospitals[ti] OR Hospital[ti] OR Inpatients[tiab] OR Inpatient[tiab] OR
‘Cross infection’[tiab] OR ‘Cross infections’[tiab] OR ‘Hospital
acquired’[tiab] OR ‘Hospital infection‘[tiab] OR ‘Hospital infections‘[tiab]
OR Animal[tiab] OR Animals[tiab])
NOT
(Review[pt] OR Meta Analysis[pt] OR News[pt] OR Comment[pt] OR
Editorial[pt] OR Letter[pt] OR comment on[ti] OR systematic review[ti]
or literature review[ti])
NOT
(Animals[Mesh] not (Animals[Mesh] and Humans[Mesh]))
CENTRAL (Cochrane)
([mh ‘Drug Resistance‘] OR Resistance:ti,ab OR Resistant:ti,ab OR
Multiresistant:ti,ab)
AND
([mh ‘Anti-Bacterial Agents‘] OR [mh ‘Macrolides‘] OR [mh ‘beta-Lactams‘]
OR Antibacterial:ti,ab OR Antibacterials:ti,ab OR Antibiotics:ti,ab OR
Antibiotic:ti,ab OR Macrolides:ti,ab OR Macrolide:ti,ab OR beta-
Lactams:ti,ab OR Antimicrobial:ti,ab OR Antimicrobials:ti,ab OR
Penicillin:ti,ab OR Methicillin:ti,ab OR ampicillin:ti,ab OR azithromycin:ti,ab
OR Cephalexin:ti,ab)
AND
([mh ‘Population Surveillance‘] OR [mh ‘Primary Health Care‘] OR [mh
‘Ambulatory Care‘] OR [mh ‘Outpatients‘] OR [mh ‘Community-Acquired
Infections‘] OR [mh ‘Demography‘] OR [mh ‘Carrier State‘] OR [mh
‘Endemic Diseases‘] OR ‘Primary care’:ti,ab OR ‘Primary healthcare’:ti,ab
Table 3 Search strategy (Continued)
OR ‘Family practice’:ti,ab OR ‘General practice’:ti,ab OR Ambulatory:ti,ab
OR Outpatients:ti,ab OR Outpatient:ti,ab OR Community:ti,ab OR
Communities:ti,ab OR Surveillance:ti,ab OR Carrier:ti,ab OR Carriage:ti,ab
OR Area:ti,ab OR Areas:ti,ab OR Region:ti,ab OR Regions:ti,ab OR
Demographic:ti,ab)
AND
([mh ‘Drug Prescriptions‘] OR [mh ‘Prescriptions‘] OR ‘therapeutic use‘:kw
OR Prescriptions:ti,ab OR Prescription:ti,ab OR Prescribing:ti,ab OR
Prescribe:ti,ab OR Prescribed:ti,ab OR Consumption:ti,ab OR Courses:ti,ab
OR Course:ti,ab OR Programme:ti,ab OR Programmes:ti,ab OR Dose:ti,ab
OR Doses:ti,ab OR Exposure:ti,ab OR Isolates:ti,ab
OR Isolated:ti,ab OR Risk:ti)
AND
([mh ‘Patients‘] OR ‘Drug therapy‘:kw OR ‘Drug effects‘:kw OR
Microbiology:kw OR Treatment:ti,ab OR Patient:ti,ab OR Patients:ti,ab
OR Patient’s:ti,ab)
NOT
([mh ‘Hospitals‘] OR [mh ‘Inpatients‘] OR [mh ‘Cross Infection‘] OR
Hospitals:ti OR Hospital:ti OR Inpatients:ti,ab OR Inpatient:ti,ab OR ‘Cross
infection‘:ti,ab OR ‘Cross infections‘:ti,ab OR ‘Hospital acquired‘:ti,ab OR
‘Hospital infection‘:ti,ab OR ‘Hospital infections‘:ti,ab OR Animal:ti,ab OR
Animals:ti,ab)
NOT
([mh Animals] not ([mh Animals] and [mh Humans]))
EMBASE
(‘Drug Resistance’/exp. OR Resistance:ti,ab OR Resistant:ti,ab OR
Multiresistant:ti,ab)
AND
(‘antibiotic agent’/exp. OR ‘Macrolide’/exp. OR ‘beta lactam’/exp. OR
Antibacterial:ti,ab OR Antibacterials:ti,ab OR Antibiotics:ti,ab OR
Antibiotic:ti,ab OR Macrolides:ti,ab OR Macrolide:ti,ab OR beta-
Lactams:ti,ab OR Antimicrobial:ti,ab OR Antimicrobials:ti,ab OR Penicillin:
ti,ab OR Methicillin:ti,ab OR ampicillin:ti,ab OR azithromycin:ti,ab OR
Cephalexin:ti,ab)
AND
(‘health survey’/exp. OR ‘Primary Health Care’/exp. OR ‘Ambulatory Care’/
exp. OR ‘Outpatient’/exp. OR ‘Community-Acquired Infection’/exp. OR
‘Demography’/exp. OR ‘heterozygote’/exp. OR ‘Endemic Disease’/exp. OR
‘Primary care’:ti,ab OR ‘Primary healthcare’:ti,ab OR ‘Family practice’:ti,ab
OR ‘General practice’:ti,ab OR Ambulatory:ti,ab OR Outpatients:ti,ab OR
Outpatient:ti,ab OR Community:ti,ab OR Communities:ti,ab OR
Surveillance:ti,ab OR Carrier:ti,ab OR Carriage:ti,ab OR Area:ti,ab OR
Areas:ti,ab OR Region:ti,ab OR Regions:ti,ab OR Demographic:ti,ab)
AND
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Table 4 Detailed reasons for exclusion
Insufficient data reported No individual patient data reported, reporting only P value 62
No data on the number of resistant isolates 49
No data on the number of patients exposed to antibiotics 47
Time between antibiotic exposure and isolation of resistance not reported 14
Contacted authors and no response received or full text not received (for conference abstracts) 23
Ineligible participant criteria Hospitalised patients >50% (or hospital-associated infections or inpatients) 89
Patients with persistent infections, device-related infections or tract abnormalities 11
Immunocompromised patients 5
>50% nursing home residents 1
Reporting gene mutations or in vitro resistant isolates 5
Ineligible exposure Prolonged antibiotic exposure (>2 weeks of exposure) 33
Pharmacokinetics of antibiotic exposure 2
Ineligible outcome data No before and after outcome data in studies in which all patients received antibiotic treatment 11
Mixed data between resistant and susceptible isolates or all patients have resistant isolates 7
Ineligible study design Case series, case reports, reviews and reports 8
Duplicates 12
Total 379
Fig. 6 Odds ratio of resistance in other respiratory isolates post-exposure to different antibiotic classes. Shaded areas indicate trials with a control group. Unshaded
areas indicate time-series studies (before and after). NGS non-groupable streptococci, M. catarrhalis Moraxella catarrhalis, S. aureus Staphylococcus aureus, S. mitis
Streptococcus mitis, Telithro telithromycin, Amoxi-clav amoxicillin-clavulanate, ß-lactams beta-lactams, Azi azithromycin, Levo levofloxacin
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Fig. 7 Co-resistance data reported among the included studies. Shaded areas indicate trials with a control group. Unshaded areas indicate time-
series studies (before and after). TMP trimethorprim, TMP-SMX trimethoprim-sulfamethoxazole, Erthro erythromycin, Erthro-sulf erythromycin-
sulfisoxazole, Telithro telithromycin, Amoxi-clav amoxicillin-clavulanate. *Data could not be extracted from three studies
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